Paragraph 4

(1)

The date on which the trial ended in the United Kingdom.

(2)

If the trial was conducted at more than one trial F1location in the United Kingdom, the dates on which the trial was ended at those F2locations, if different from the date referred to in sub-paragraph (1).

F3(3)

If the trial was conducted at any trial locations outside the United Kingdom, a statement as to whether the trial has ended at any of those locations and—

(a)

if ended, the date on which the trial ended; or

(b)

if not ended, the anticipated end date of the trial.

Annotations

Textual amendments

F1: Word in Sch. 3 Pt. 4 para. 4(2) substituted (28.4.2026) by The Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025 (S.I. 2025/538), regs. 1(2), 39(6)(c)(i)(aa)
F2: Word in Sch. 3 Pt. 4 para. 4(2) substituted (28.4.2026) by The Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025 (S.I. 2025/538), regs. 1(2), 39(6)(c)(i)(bb)
F3: Sch. 3 Pt. 4 para. 4(3) substituted (28.4.2026) by The Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025 (S.I. 2025/538), regs. 1(2), 39(6)(c)(ii)

Notes on Schedule 3

Textual amendments

F1: Words in Sch. 3 heading substituted (28.4.2026) by The Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025 (S.I. 2025/538), regs. 1(2), 39(2)